Primera Therapeutics aims to edit gene mutations to treat mitochondrial disease, which affects an estimated 1 in 5,000 people worldwide and often results in early childhood death. The company will collaborate with biotech firm Cellectis.
The Mayflower Bioventures accelerator, a collaboration between Mayo Clinic and the Hibiscus BioVentures investment firm, began operating in August.
“It requires a team effort to drive this program forward into the clinic and for patients who are suffering with these dreadful diseases,” said Stephen Ekker, PhD, dean of the Mayo Clinic Graduate School of Biomedical Sciences and an inventor for Primera, in a Dec. 29 Cellectis news release.
If Primera exercises a worldwide licensing option, Cellectis could yield up to $750 million in development and sales milestones.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
